Moderna (NASDAQ: MRNA) — Company Overview, News & Financial Data
Moderna is a biotechnology company known for its mRNA technology, aiming to revolutionize vaccines and treatments.
Moderna
Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA medicines and vaccines. The company utilizes proprietary messenger RNA technology platforms to design therapeutics and preventive vaccines targeting infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular ailments. Its commercial portfolio includes preventive vaccines for viral respiratory pathogens alongside a pipeline of clinical candidates across multiple therapeutic areas. The company maintains biomanufacturing, research, and commercial operations internationally.
Snapshot
Operations
Products and/or services of Moderna
- Respiratory Vaccines: Commercial production and global supply of messenger RNA vaccines protecting against respiratory viral infections, including formulations for COVID-19 and respiratory syncytial virus administered across international healthcare markets.
- Infectious Disease Pipeline: Clinical development of investigational mRNA vaccines targeting latent and emerging pathogens, including cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, herpes simplex virus, and seasonal influenza strains.
- Immuno-Oncology Therapeutics: Advancement of individualized neoantigen therapies and off-the-shelf mRNA cancer vaccines designed to stimulate targeted T-cell immune responses against specific tumor antigens in combination with checkpoint inhibitors.
- Rare Disease Therapies: Development of systemic messenger RNA therapeutics designed to instruct human cells to produce functional intracellular or secreted proteins, addressing metabolic deficiencies such as propionic acidemia and methylmalonic acidemia.
- Autoimmune and Cardiovascular Therapeutics: Clinical research into localized and systemic mRNA formulations designed to express therapeutic proteins, promote angiogenesis, or modulate immune pathways in heart failure, ischemic heart disease, and autoimmune conditions.
- Manufacturing Facilities: Operation of specialized biomanufacturing plants and technological hubs, including facilities in Norwood, Massachusetts, dedicated to clinical supply production, lipid nanoparticle formulation, and large-scale commercial drug substance manufacturing.
Moderna executive team
- Stéphane BancelCEO & Director
- Stephen HogePresident
- James M. MockChief Financial Officer
- Shannon Thyme KlingerChief Legal Officer & Corporate Secretary
- Juan AndresChief Operating Officer
- Lavina TalukdarSenior VP & Head of Investor Relations
- Chris RidleyVP & Global Head of Communications
- Tracey FranklinChief People & Digital Technology Officer
- Charbel HaberSenior VP & Head of Global Regulatory Science
- Patrick Norman BergstedtSenior Vice President of Commercial Vaccines
Latest news about Moderna
Moderna rises 2.2% on Nasdaq-100 inclusion
United StatesMerck and Moderna melanoma therapy meets Phase 3 goals
United StatesModerna receives FDA approval for mFLUSIVA flu vaccine
United StatesModerna sales total $145M as biotech firm reports Q2 results
United StatesModerna advances mRNA-4200 cancer therapy clinical trial
United StatesModerna's Flu Vaccine Moves Closer to FDA Approval
Australia
Key financials
Reported results for Moderna, in USD.
- Market cap
- 88.9B
- Revenue (TTM)
- 2.2B
- P/E ratio
- —
- EPS (diluted, TTM)
- -8.0
- Dividend yield
- —
- Profit margin
- -141.4%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 1.9B | -3.1B | -2.8B | |
| 3.2B | -3.9B | -3.6B | |
| 6.8B | -4.2B | -4.7B | |
| 18.9B | 9.4B | 8.4B |